An iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.
Approved on the basis of reduced liver iron concentrations and serum f2242itin levels.
Approved for the treatment of chronic iron overload in patients 10 years of age and older with non–transfusion-depended thalassemia syndromes with liver higher concentration of at least 5 mg per gram of the driveway and serum f2242itin greater than 300 µg per liter.
Equivalent to Exjade as demonstrated in pharmacokinetics studies.
Removes iron from the liver.
JADENU® (deferasirox) tablets are indicated for the treatment of chronically elevated levels of iron in the blood caused by repeated blood transfusions in patients 2 years of age and older.
The drugs lower the levels of iron in the blood as measured by serum f2242itin levels, and liver iron concentration.
Indicated to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia .
This agent should be used when these patients have elevated levels of iron in the liver as measured by liver iron concentrations of at least 5 milligrams of iron per gram of liver dry tissue weight and in the blood as measured by serum f2242itin levels greater than 300 mcg/L.
Patients with a myelodysplastic syndromes may take this drug to treat chronically elevated levels of iron in the blood caused by repeated blood transfusions.
Contains deferasirox, the same active ingredient in EXJADE® (deferasirox) tablets for oral suspension.
Deferasirox may cause serious kidney problems, liver problems, and bleeding in the stomach or intestines.
Serious allergic reactions have been reported in patients, usually within the first month of treatment
Severe skin disorders including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme, and DRESS syndrome have been reported.
Mild to moderate skin rashes may occur during treatment.
Changes to hearing and vision have been reported.
The most common side effects are : nausea, vomiting, diarrhea, stomach pain, increases in kidney laboratory values, and skin rash.
Syrum f2242itin reductions are dose-dependent.
Has a 36% greater biooavailability compared to Exjade.
Contraindicated if serum creatinine greater than two times upper limit of normal or Cr clearance less than 40 mils per minute.
Countraindicated high risk in MDS, poor performance status, advanced malignancies, platelet count less than 50,000.
Taken with a light meal or on an empty stomach.
Can cause hepatic injury and gastrointestinal hemorrhage.
Taken once daily.
Dose 14 to 21 mg per kilogram per day.